CA2243577A1 - Methods for purification and use of erythropoietin binding protein - Google Patents

Methods for purification and use of erythropoietin binding protein

Info

Publication number
CA2243577A1
CA2243577A1 CA002243577A CA2243577A CA2243577A1 CA 2243577 A1 CA2243577 A1 CA 2243577A1 CA 002243577 A CA002243577 A CA 002243577A CA 2243577 A CA2243577 A CA 2243577A CA 2243577 A1 CA2243577 A1 CA 2243577A1
Authority
CA
Canada
Prior art keywords
ebp
protein
epo
methods
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002243577A
Other languages
French (fr)
Other versions
CA2243577C (en
Inventor
Steven A. Middleton
Dana Johnson
Frank J. Mcmahon
Linda S. Mulkahy
Linda K. Jolliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho Pharmaceutical Corporation
Steven A. Middleton
Dana Johnson
Frank J. Mcmahon
Linda S. Mulkahy
Linda K. Jolliffe
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corporation, Steven A. Middleton, Dana Johnson, Frank J. Mcmahon, Linda S. Mulkahy, Linda K. Jolliffe, Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho Pharmaceutical Corporation
Priority to CA002573196A priority Critical patent/CA2573196A1/en
Priority claimed from PCT/US1997/000932 external-priority patent/WO1997027219A1/en
Publication of CA2243577A1 publication Critical patent/CA2243577A1/en
Application granted granted Critical
Publication of CA2243577C publication Critical patent/CA2243577C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The extracellular domain of the human erythropoietin receptor (EPO binding protein, EBP) has been expressed and overproduced in E. coli. Control of oxygen levels and pH during high density fermentation allows the production of only the protein variant with the native amino terminus. Methods disclosed permit the efficient recovery of purified EBP which quantitatively binds EPO. The active purified protein competes with membrane associated EPO receptor for binding [125I]EPO
and neutralizes EPO dependent stimulation in a cell based proliferation assay. Further, the radioligand equilibrium binding constant for this interaction has been determined by immobilizing EBP on agarose gel via a free cysteine. The EBP of the present invention has many uses including the structural determination of the protein by NMR or crystallography, in drug design and discovery, and as a therapeutic. A
fusion protein of EBP and an immunoglobulin heavy chain was also produced. This protein, termed EBP-Ig, is a preformed dimerization template and is also useful in drug design and discovery methods.
CA002243577A 1996-01-23 1997-01-22 Methods for purification and use of erythropoietin binding protein Expired - Lifetime CA2243577C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002573196A CA2573196A1 (en) 1996-01-23 1997-01-22 Methods for purification and use of erythropoietin binding protein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1046996P 1996-01-23 1996-01-23
US2212996P 1996-07-18 1996-07-18
US60/010,469 1996-07-18
US60/022,129 1996-07-18
PCT/US1997/000932 WO1997027219A1 (en) 1996-01-23 1997-01-22 Methods for purification and use of erythropoietin binding protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002573196A Division CA2573196A1 (en) 1996-01-23 1997-01-22 Methods for purification and use of erythropoietin binding protein

Publications (2)

Publication Number Publication Date
CA2243577A1 true CA2243577A1 (en) 1997-07-31
CA2243577C CA2243577C (en) 2007-06-05

Family

ID=38137605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002243577A Expired - Lifetime CA2243577C (en) 1996-01-23 1997-01-22 Methods for purification and use of erythropoietin binding protein

Country Status (1)

Country Link
CA (1) CA2243577C (en)

Also Published As

Publication number Publication date
CA2243577C (en) 2007-06-05

Similar Documents

Publication Publication Date Title
ATE522610T1 (en) HUMAN METABOTROPIC GLUTAMA RECEPTOR SUBTYPES (HMR6) AND RELATED DNA COMPOUNDS
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
HK1008021A1 (en) Growth hormone receptor
EP0613944A3 (en) Methods for regulating the immune response using CTLA4-binding molecules and IL4-binding molecules.
EP0686161A4 (en) NOVEL HUMAN -g(b) 2? INTEGRIN ALPHA SUBUNIT
RO117177B1 (en) Human and murine ob recombinant proteins, dna sequence encoding the same, process for producing said protein and conjugate thereof
HK1008830A1 (en) Mammalian receptors for interleukin
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
IL123189A0 (en) Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides
DE69939330D1 (en) GROWTH FACTOR HOMOLOGIST ZVEGF-3
ATE310098T1 (en) DNA CODING FOR GLUTAMIC ACID-CONTROLLED CHLORIDE CHANNELS
EP1243597A3 (en) Receptors for human interleukin-12
EP0909274A4 (en) Methods for purification and use of erythropoietin binding protein
CA2243577A1 (en) Methods for purification and use of erythropoietin binding protein
AU2818095A (en) Colon specific gene and protein
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
DK326289A (en) PROCEDURE FOR MANUFACTURING A PROTEIN FROM YEAR FUNGES USING AN INDUCERABLE SYSTEM, AND VECTORS AND TRANSFORMED STUES FOR USING THE PROCEDURE
EP0643728A4 (en) Icam-related protein.
ATE272072T1 (en) METHOD FOR PURIFICATION OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST FROM RECOMBINANT E.COLI
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
Takeuchi et al. Purification of human lung angiotensin-converting enzyme by high-performance liquid chromatography: Properties and N-terminal amino acid sequence
WO1996023070A3 (en) HUMAN RETINOID X RECEPTOR - GAMMA (hRXR-GAMMA)
ATE260339T1 (en) ANTIBODIES TO HUMAN RESTRICTIN
ATE339448T1 (en) METHOD FOR SEPARATING GLYCOSYLATED AND NON-GLYCOSYLATED PROTEINS

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170123